Penelope A. Bryant

Penelope A. Bryant

Auto-generated profile, based on publicly available information

Penelope A. Bryant

Infectious Diseases Department, Royal Children's Hospital Melbourne , Parkville

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BMBrendan J McMullan
Brendan J McMullan
DADavid Andresen
David Andresen
CBChristopher Charles Blyth
Christopher Charles Blyth
MAMinyon L Avent
Minyon L Avent
Asha BowenAsha Bowen
Asha Bowen
PBPenelope A Bryant
Penelope A Bryant


16 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SWStacie S. Wang
Stacie S. Wang
RKRishi S Kotecha
Rishi S Kotecha
ABAnne Bernard
Anne Bernard
CBChristopher C. Blyth
Christopher C. Blyth
BMBrendan J. McMullan
Brendan J. McMullan
GHGabrielle M. Haeusler
Gabrielle M. Haeusler

21 August 2020 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
SKSeilesh Kadambari
Seilesh Kadambari
YAYara-Natalie Mbbs Abo
Yara-Natalie Mbbs Abo
LPLinny Kimly Phuong
Linny Kimly Phuong
JOJoshua Fracp Osowicki
Joshua Fracp Osowicki
PBPenelope A. Fracp Bryant
Penelope A. Fracp Bryant
An abstract is unavailable. This article is available as a PDF only.

8 February 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
SBSaurav Basu
Saurav Basu
RCRaul Copana
Raul Copana
RMRonaldo Jr. Bpharm Morales
Ronaldo Jr. Bpharm Morales
SASuvaporn Anugulruengkitt
Suvaporn Anugulruengkitt
TPThanyawee Mhs Puthanakit
Thanyawee Mhs Puthanakit
PBPenelope A. Bryant
Penelope A. Bryant
Antimicrobial resistance is a global health threat and there is an urgent need to manage antibiotic use to slow its development. However, antimicrobial stewardship interventions in low- and middle-income countries (LMIC) have been limited in terms of their resourcing, feasibility and effectiveness in the face of greater challenges in child mortality. We sought to gather together examples of antibiotic use problems faced by clinicians in LMIC, many of which are unique to these settings, and real-world antimicrobial stewardship solutions identified, with the goal of learning broader lessons that might be applicable across LMIC.

8 February 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
YAYara-Natalie Abo
Yara-Natalie Abo
BFBridget Freyne
Bridget Freyne
DKDiana Mbbs Kululanga
Diana Mbbs Kululanga
PBPenelope A. Bryant
Penelope A. Bryant
Background: Antimicrobial stewardship (AMS) is central to the World Health Organisation Global Action Plan against antimicrobial resistance (AMR). If antibiotics are used without restraint, morbidity and mortality from AMR will continue to increase. In resource-rich settings, AMS can safely reduce antibiotic consumption. However, for children in low- and middle-income countries (LMIC), the impact of different AMS interventions is unknown. Aim: To determine the impact of different AMS interventions on antibiotic use and clinical and microbiologic outcomes in children in LMIC. Methods: MEDLINE, Embase and PubMed were searched for studies of AMS interventions in pediatric population in LMIC settings. Controlled trials, controlled before-and-after studies and interrupted time series studies were included. Outcomes assessed were antibiotic use, multidrug-resistant organism (MDRO) rates, clinical outcomes and cost. Results: Of 1462 studies, 34 met inclusion criteria including a total population of >5,000,000 in 17 countries. Twenty were in inpatients, 2 in ED, 10 in OPD and 2 in both. Seven studies were randomized controlled trials. All types of interventions reported a positive impact on antibiotic prescribing. AMS bundles with education, and clinical decision tools appeared more effective than guidelines alone. AMS interventions resulted in significantly decreased clinical infections (4/4 studies) and clinical failure (2/2) and reduced MDRO colonization rate (4/4). There was no concomitant increase in mortality (4/4 studies) or length of stay (2/2). Conclusion: Multiple effective strategies exist to reduce antibiotic consumption in LMIC. However, marked heterogeneity limit conclusions regarding the most effective approach, particularly regarding clinical outcomes. Overall, AMS strategies are important tools in the reduction of MDRO-related morbidity in children in LMIC.